Table 2 Distribution of baseline clinical characteristics by nanoString hypoxia signature result.

From: Technical development and validation of a clinically applicable microenvironment classifier as a biomarker of tumour hypoxia for soft tissue sarcoma

 

Manchester cohort, n = 126

VORTEX-Biobank cohort, n = 154

NanoString hypoxia result

P

NanoString hypoxia result

P

Low

High

Low

High

n = 73

n = 53

n = 84

n = 70

Age (years)

57 (17–86)

63 (23–94)

0.34

58 (23–88)

61 (26–85)

0.06

Size (cm)

8 (2.3–27)

10.3 (2.5–80)

0.04

8.7 (1.4–26)

10.0 (2.5–34)

0.06

Sex

 Female

31

21

0.75

36

27

0.54

 Male

42

32

48

43

WHO PS

      

 0/1

69

44

0.1

68

57

 

 2/3

2

6

2

1

0.66

 Unknown

2

3

16

10

 

Surgical margin*

 Intralesional

0

1

0.57

   

 Marginal

18

16

   

 Wide

14

10

   

 Unknown

41

26

   

Surgical margin*

 R0

   

79

60

0.08

 R1

   

5

10

Depth

      

 Superficial

14

13

0.47

17

12

0.62

 Deep

59

40

67

58

Grade

 1

10

1

0.001

6

2

0.01

 2

24

15

21

8

 3

28

36

58

59

 Unknown

11

0

–

–

Histology

 LMS

4

7

0.16

6

1

 

 MFS

14

7

21

23

 

 MPNST

8

2

2

3

 

 MLPS

5

1

15

3

0.05

 SS

5

3

3

2

 

 UPS

16

20

22

28

 

 Other

21

13

15

10

 
  1. WHO PS World Health Organisation performance status, MPNST malignant peripheral nerve sheath tumour, LMS leiomyosarcoma, MLPS myxoid liposarcoma, MFS myxofibrosarcoma, SS synovial sarcoma, UPS undifferentiated pleomorphic sarcoma.
  2. P values are from the Chi2 or Mann–Whitney U test for categorical and continuous variables, respectively.
  3. *Surgical margins were reported by different systems for the Manchester and VORTEX-Biobank cohorts.
  4. The statistically significant p values are shown in bold.
Back to article page